Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396387 | 0.92 | PTGS2 (0.37) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396479 | 0.88 | FFAR1 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396358 | 0.86 | ALOX5 (0.42) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396368 | 0.86 | SLC7A5 (0.42) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396462 | 0.86 | ITGB3 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396473 | 0.86 | FFAR1 (0.42) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396446 | 0.84 | MARS1 (0.37) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396529 | 0.83 | SPHK1 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396398 | 0.81 | NPY4R (0.37) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13396493 | 0.80 | KCNH2 (0.36) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | CA12 4275/4885CA1 4365/4885CA2 2916/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | CA12 4290/4885CA1 4414/4885CA2 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.